OncLive TV

Cristina Gasparetto, MD, an associate professor of medicine, Duke University Medical Center, and director, Multiple Myeloma Program at Duke Cancer Institute, discusses key trials in relapsed/refractory multiple myeloma.

Pashtoon M. Kasi, MBBS, MD, MS, hematologist, internist, oncologist, Mayo Clinic, discusses the comparison of circulating tumor DNA tests, tissue, and liquid biopsies, in a study of patients with colorectal cancer.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the prevalence of genomic testing in urothelial cancer.

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses treatment deintensification for patients with HPV-related oropharyngeal squamous cell carcinoma.

Jane L. Meisel, MD, an assistant professor, Department of Hematology and Medical Oncology and Department of Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses optimizing genomic assays in early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Vinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, discusses the importance of assessing for minimal residual disease in acute lymphoblastic leukemia.

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington and hematologist/oncologist at Seattle Cancer Care Alliance, discusses the role of venetoclax (Venclexta) in multiple myeloma.

Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy and director of clinical research, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses the rationale to explore triplet therapy in BRAF V600-mutant melanoma.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.

Paul D. Nathan, MBBS, PhD, FRCP, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib plus trametinib in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses the FDA approval of darolutamide (Nubeqa) in nonmetastatic castration-resistant prostate cancer (M0CRPC).

David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the predictive value of circulating tumor DNA (ctDNA) in BRAF-mutant melanoma.

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, and hematology oncologist, Seattle Cancer Care Alliance, discusses the potential of fostamatinib (Tavalisse) in the treatment of patients with chronic immune thrombocytopenia (ITP).

Leonard G. Gomella, MD, discusses the role of prostate-specific antigen screening in the early detection of prostate cancer.

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the phase III E3A06 study, which looked at the effects of lenalidomide in patients with smoldering myeloma.

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses the predictive value of BRAF V600E mutations in metastatic colorectal cancer (mCRC).

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses immunotherapy combination in hepatocellular carcinoma (HCC).

Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses results from the 5-year analysis of the combination of dabrafenib and trametinib in patients with BRAF V600E-mutant melanoma.

Daniel Vaena, MD, hematologist/medical oncologist and hematologist, West Cancer Center, discusses progress made in the treatment of patients with metastatic prostate cancer.

Drew Moghanaki, MD, MPH, discusses the impact of the PACIFIC trial on stage III lung cancer treatment.

Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the plans for the CA045-001 trial, an international, multicenter study that is comparing bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses future directions in prostate cancer.

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the use of polatuzumab vedotin (Polivy) in diffuse large B-cell lymphoma (DLBCL).

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of radiopharmaceuticals in the treatment of patients with prostate cancer.